Taysha Gene Therapies Inc. (TSHA): A Promising Biotech on Rett Syndrome Drug Prospects [Yahoo! Finance]
Taysha Gene Therapies, Inc. (TSHA)
Company Research
Source: Yahoo! Finance
The trial is evaluating TSHA-102, a gene therapy for Rett syndrome. The trial is poised to evaluate 15 females between the ages of 6 and 22 years with Rett syndrome. The focus is on ascertaining the response rate, which is the percentage of patients who gain or regain one or more of 28 natural history-defined developmental milestones. The company will complete dosing in both the REVEAL pivotal trial and ASPIRE trial in the second quarter. The Rett syndrome trial comes in Jefferies, reiterating Taysha Gene Therapies as a promising biotech company poised for significant growth in 2026. The research firm expects the stock to receive a boost from pivotal trial data and regulatory milestones across multiple therapeutic areas. The firm has touted the company's Rett syndrome therapy, TSHA-102, owing to its potential to generate $2 billion in peak revenue. Taysha Gene Therapies Inc. (NASDAQ:TSHA) is a clinical-stage biotech company developing adeno-associated virus (AAV)-based gene ther
Show less
Read more
Impact Snapshot
Event Time:
TSHA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TSHA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TSHA alerts
High impacting Taysha Gene Therapies, Inc. news events
Weekly update
A roundup of the hottest topics
TSHA
News
- Taysha Gene Therapies (NASDAQ:TSHA) had its "strong-buy" rating reaffirmed by analysts at Raymond James Financial, Inc..MarketBeat
- Taysha Gene Therapies (NASDAQ:TSHA) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $12.00 price target on the stock.MarketBeat
- Taysha Gene Therapies Announces Progress Across TSHA-102 Pivotal Gene Therapy Program in Rett SyndromeGlobeNewswire
- Taysha Gene Therapies (NASDAQ:TSHA) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.MarketBeat
- Taysha Gene Therapies (NASDAQ:TSHA) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=TSHA&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall SMarketBeat
TSHA
Earnings
- 11/4/25 - In-Line
TSHA
Sec Filings
- 1/14/26 - Form 4
- 1/14/26 - Form 4
- 1/14/26 - Form 4
- TSHA's page on the SEC website